Preliminary Cost-effectiveness and Cost-utility of Nasopharyngeal Carcinoma Screening with the Novel Biomarker Anti-BNLF2b Total Antibody

作者：Jiali Quan, Chunlan Zhuang, Yue Huang, Xia Yu, Fan Liu, Jinrong Hao, Tingdong Li, Yingying Su, Shoujie Huang, Shengxiang Ge, Ting Wu, Mingfang Ji, Jun Zhang, Ningshao Xia · 发表于：Cancer Epidemiology Biomarkers & Prevention · 年份：2025 · DOI：10.1158/1055-9965.epi-25-0648 · 被引用次数：3 · 研究领域：Head and Neck Cancer Studies、Cervical Cancer and HPV Research、Viral-associated cancers and disorders

BACKGROUND: Nasopharyngeal carcinoma (NPC) is notably prevalent in southern China and Southeast Asia, highlighting the need for effective screening strategies. METHODS: In Zhongshan, Guangdong, a screening program involving 24,852 healthy Cantonese individuals aged 30 to 69 compared the anti-BNLF2b total antibody (P85-Ab) with the Epstein-Barr nuclear antigen 1 immunoglobulin A (EBNA1-IgA) and viral capsid antigen immunoglobulin A (VCA-IgA) testing (two-antibody method). We examined the cost-effectiveness and cost-utility of screening for NPC with the novel biomarker P85-Ab in China. RESULTS: The P85-Ab screening required 540 initial tests and 8 endoscopies per detected case, compared with 731 tests and 18 endoscopies for two-antibody screening. When the P85-Ab test was priced at ¥133.48, ¥37.48 higher than the two-antibody test, both strategies had an equivalent screening cost of ¥74,039.03 per confirmed NPC case. At a threshold of 0.46 times the per capita GDP per life year, P85-Ab screening remained cost-effective compared with two-antibody screening when the incremental prices of the alternative test were below ¥22.37 (short-term), ¥80.51 (intermediate-term), and ¥152.02 (long-term). When compared with the no-screening strategy, the maximum acceptable prices were ¥51.69 (short-term), ¥181.06 (intermediate-term), and ¥341.82 (long-term). At a threshold of 0.51 times the per capita GDP per quality-adjusted life year, the corresponding incremental prices and maximum acceptab...